Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

NCT06223958 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG: OTX-TKI (axitinib implant)
DRUG: Aflibercept

Sponsor

Ocular Therapeutix, Inc.

Collaborators

[object Object]
[object Object]